These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22473911)

  • 1. Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis.
    Kim MY; Suk KT; Baik SK; Kim HA; Kim YJ; Cha SH; Kwak HR; Cho MY; Park HJ; Jeon HK; Park SY; Kim BR; Hong JH; Jo KW; Kim JW; Kim HS; Kwon SO; Chang SJ; Baik GH; Kim DJ
    Hepatology; 2012 Sep; 56(3):1053-62. PubMed ID: 22473911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe portal hypertension in cirrhosis: evaluation of perfusion parameters with contrast-enhanced ultrasonography.
    Jeong WK; Kim TY; Sohn JH; Kim Y; Kim J
    PLoS One; 2015; 10(3):e0121601. PubMed ID: 25798930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatic transit times and liver elasticity compared with meld in predicting a 1 year adverse clinical outcome of a clinically diagnosed cirrhosis].
    Koller T; Piešťanská Z; Hlavatý T; Holomáň J; Glasa J; Payer J
    Vnitr Lek; 2016; 62(5):351-9. PubMed ID: 27319227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical value of contrast-enhanced ultrasound in evaluating portal hypertension in patients with decompensated liver cirrhosis].
    Zhuang Y; Ding H; Han H; Mao F; Luo JJ; Chen SY; Wang WP
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):270-4. PubMed ID: 27470625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring Intrahepatic Vascular Changes Using Contrast-Enhanced Ultrasonography to Predict the Prognosis of Alcoholic Hepatitis Combined with Cirrhosis: A Prospective Pilot Study.
    Park MS; Hong S; Lim YL; Kang SH; Baik SK; Kim MY
    Gut Liver; 2018 Sep; 12(5):555-561. PubMed ID: 29699059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
    Kim MY; Baik SK; Suk KT; Yea CJ; Lee IY; Kim JW; Cha SH; Kim YJ; Um SH; Han KH
    Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
    Kim MY; Baik SK; Park DH; Lim DW; Kim JW; Kim HS; Kwon SO; Kim YJ; Chang SJ; Lee SS
    Liver Int; 2007 Oct; 27(8):1103-10. PubMed ID: 17845539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors.
    Llop E; Berzigotti A; Reig M; Erice E; Reverter E; Seijo S; Abraldes JG; Bruix J; Bosch J; García-Pagan JC
    J Hepatol; 2012 Jan; 56(1):103-8. PubMed ID: 21827733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of hepatic vein arrival time performed with contrast-enhanced ultrasonography for HCV liver cirrhosis.
    Makhlouf NA; Moustafa EF; Hassany SM
    Arab J Gastroenterol; 2022 Aug; 23(3):195-200. PubMed ID: 35688684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis.
    Berzigotti A; Seijo S; Arena U; Abraldes JG; Vizzutti F; García-Pagán JC; Pinzani M; Bosch J
    Gastroenterology; 2013 Jan; 144(1):102-111.e1. PubMed ID: 23058320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.
    Villanueva C; Albillos A; Genescà J; Abraldes JG; Calleja JL; Aracil C; Bañares R; Morillas R; Poca M; Peñas B; Augustin S; Garcia-Pagan JC; Pavel O; Bosch J
    Hepatology; 2016 Jan; 63(1):197-206. PubMed ID: 26422126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis.
    Berzigotti A; Nicolau C; Bellot P; Abraldes JG; Gilabert R; García-Pagan JC; Bosch J
    J Hepatol; 2011 Aug; 55(2):307-14. PubMed ID: 21167236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
    Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
    Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response.
    Baik SK; Kim JW; Kim HS; Kwon SO; Kim YJ; Park JW; Kim SH; Chang SJ; Lee DK; Han KH; Um SH; Lee SS
    Radiology; 2006 Aug; 240(2):574-80. PubMed ID: 16864678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis.
    Lemoine M; Katsahian S; Ziol M; Nahon P; Ganne-Carrie N; Kazemi F; Grando-Lemaire V; Trinchet JC; Beaugrand M
    Aliment Pharmacol Ther; 2008 Nov; 28(9):1102-10. PubMed ID: 18691352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
    Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
    World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging.
    Gouya H; Grabar S; Vignaux O; Saade A; Pol S; Legmann P; Sogni P
    Eur Radiol; 2016 Jul; 26(7):1981-90. PubMed ID: 26373753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis.
    Lisotti A; Azzaroli F; Buonfiglioli F; Montagnani M; Cecinato P; Turco L; Calvanese C; Simoni P; Guardigli M; Arena R; Cucchetti A; Colecchia A; Festi D; Golfieri R; Mazzella G
    Hepatology; 2014 Feb; 59(2):643-50. PubMed ID: 24038116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.